Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial

• Egile Nagusiak: Mark Turner (Egilea), Athanasia Papadimitriou (Egilea), Peter Winkle (Egilea), Nathan Segall (Egilea), Michael Levin (Egilea), Matthew Doust (Egilea), Casey Johnson (Egilea), Gregg Lucksinger (Egilea), Carlos Fierro (Egilea), Paul Pickrell (Egilea), Marsha Raanan (Egilea), Vianney Tricou (Egilea), Astrid Borkowski (Egilea), Derek Wallace (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2020-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Takeda has developed a live-attenuated dengue tetravalent vaccine candidate (TAK-003) which has been shown to be immunogenic with acceptable reactogenicity in phase 1 trials. In agreement with World Health Organization prequalification requirements for dengue vaccines, Takeda has manufactured a lyop...